Temple University Health System’s preparations for and treatment of patients amidst the coronavirus pandemic continue to be part of the media’s COVID-19 coverage.
- Tony S. Reed, MD, PhD, MBA, Executive Vice President and Chief Medical Officer of Temple Health, spoke with CBS3 about the latest rise in COVID-19 cases.
- Jason C. Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, Clinical Professor and Director of the Postgraduate Year Two Infectious Diseases Residency at the Temple University School of Pharmacy and Clinical Pharmacist Specialist in Infectious Diseases at Temple University Hospital, joined a group of experts from the Infectious Diseases Society of America (IDSA) to discuss Paxlovid, an oral antiviral medication for COVID-19, and drug interactions, its distribution/availability, and other topics.
- Temple Health offered comments to the Philadelphia Inquirer and FOX29 about shortages in the United States of an injectable dye used in certain medical scans following a production shutdown overseas due to COVID-19. Temple is following recommendations of national medical societies and making every effort to provide patients necessary and appropriate care without interruption. Where appropriate, those efforts may include ordering alternative tests, including non-contrast CAT scans, MRI scans, PET/CT scans and ultrasound examinations.
- Bryce McKibben, Senior Director of Policy and Advocacy at the Hope Center for College, Community and Justice at the Lewis Katz School of Medicine at Temple University, was interviewed for a piece in Marketplace about federal guidelines for using COVID relief funds for higher-education institutions.